ArticleCancer2021
Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Adiponectin receptor agonist AdipoRon induces autophagy via AdipoR1/2-AMPK pathway and suppresses tumor progression in ovarian cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer.Research square · 2026Article
- Using large language models to identify prediagnostic clinical features of ovarian cancer from healthcare records: a population-based case-control study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- Clinical Features of Malignant Ovarian Germ Cell Tumors According to Demographic and Pathologic Characteristics.Health science reports · 2026Article
- Study of Estrogen Receptor Alpha Gene Polymorphisms (International journal of molecular sciences · 2026Article
- Diagnostic Timing and Ovarian Cancer Survival.JAMA network open · 2026Article
- Symptom-related care and diagnoses before ovarian cancer detection: Patterns and differences by cancer stage.Gynecologic oncology · 2026Article
- IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1-Dependent Ferroptosis.Human mutation · 2026Article
- Epidemiology and risk factors for ovarian cancer incidence in the USA: a multilevel analysis.Journal of global health · 2025Article
- Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population.Cancer research communications · 2025Article
- CEBPB regulates ERK1/2 activity through SOS1 and contributes to ovarian cancer progression.Medical oncology (Northwood, London, England) · 2025Article
- Treatment With a Nonaromatizable Androgen for Transgender Man With a Hormone-sensitive Ovarian Cancer.JCEM case reports · 2025Article
- A Technique for Re-siting a Midline Transverse Loop Colostomy.Gynecologic oncology reports · 2025Article
- Cross-sectional analysis of triglycerides and serum uric acid association in ovarian cancer patients.Frontiers in oncology · 2025Article
- Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.Gynecologic oncology · 2024Article
- Article
- Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review.BMJ oncology · 2024Article
- Black-White differences in uterine cancer symptomatology and stage at diagnosis.Gynecologic oncology · 2024Article
- Association Between Purchase of Over-the-Counter Medications and Ovarian Cancer Diagnosis in the Cancer Loyalty Card Study (CLOCS): Observational Case-Control Study.JMIR public health and surveillance · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatients with ovarian cancer often present with late-stage disease and nonspecific symptoms, but little is known about factors affecting the time to diagnosis (TTD) in the United States.
methodsA retrospective, population-based study of the Surveillance, Epidemiology, and End Results-Medicare database was conducted. It included women 66 years old or older with stage II to IV epithelial ovarian cancer with at least 1 code for abdominal/pelvic pain, bloating, difficulty eating, or urinary symptoms within 1 year of the cancer diagnosis. TTD was defined from the first claim with a prespecified symptom to the ovarian cancer diagnosis. Kruskal-Wallis tests were used to assess for differences in TTD by group medians. Univariate and generalized linear models with a log-link function evaluated TTD by covariables.
resultsFor the 13,872 women analyzed, the mean and median times to diagnosis were 2.9 and 1.1 months, respectively. The median TTD differed significantly by first symptom (P < .001), number of symptoms (P < .001), and first physician specialty seen (P < .001). In a multivariable analysis, TTD differed significantly according to race/ethnicity (P < .001), geographic region (P = .001), urban-rural location (P = .031), emergency room presentation (P < .001), and number of specialties seen (P < .001). A shorter TTD was associated with a diagnosis in 2006-2010 (relative risk [RR], 0.92; 95% confidence interval [CI], 0.87-0.98) or 2011-2015 (RR, 0.87; 95% CI, 0.81-0.93) in comparison with 1992-1999.
conclusionsThe time from a symptomatic presentation to care to a diagnosis of ovarian cancer is influenced by clinical and demographic variables. This study's findings reinforce the importance of educating all physicians on ovarian cancer symptoms to aid in diagnosis. LAY SUMMARY: Ovarian cancer is often diagnosed once disease has spread because the classic symptoms of ovarian cancer-abdominal or pelvic pain, bloating, difficulty eating, and urinary issues-can be mistaken for other problems. This study examined the time between when women with classic ovarian cancer symptoms went to a physician and when they received a cancer diagnosis in a large database population. The authors found that the time to diagnosis differed according to the type and number of symptoms and what type of physician a woman saw as well as factors such as race, geographic location, and year of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.